Leucémie aiguë myéloïde avec mutation FLT3-TKD : bon ou mauvais pronostic ? Analyse du sous-groupe de l’essai RATIFY [1]Volume 26, numéro 6, Décembre 2020
[1]Voso M.T., Larson R.A., Jones D. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a sub analysis from the RATIFY trial. Blood Adv. 2020;4:4945-4954.
[2]Dohner H., Estey E., Grimwade A. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424-447.
[3]Stone R.M., Mandrekar S.J., Sanford B.L. Midaustaurin plus Chemotherapy for acute myeloid leukemia with FLT3 mutations. NEJM. 2017;377:454-464.
[4]Perry M., Bertoli S., Rocher C. FLT3-TKD mutations associated with NPM1 mutations define a favorable-risk group in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2018;18:e545-e550.